Ridloff Elena

Director Elena Ridloff sells entire 12,000-share position in KYMR for $1.0M, exiting completely as company burns $82.2M annually.

Elena Ridloff, a director of Kymera Therapeutics, conducted 3 separate sales totaling 12,000 shares for $1,024,660.38 between March 31 and April 1, 2026, at prices ranging from $85.19 to $86.05. This represents a complete liquidation of her holdings (from 12,000 shares to 0 shares, a -100.0% change). The sales occurred near the company's 52-week high of $95.03 but the stock now trades at $84.93, down 5.7% over the past 30 days. The timing is notable given Kymera's operational stress: the company reported net income of $-82,175,000.00 in its most recent full fiscal year and quarterly revenue of only $2,764,000.00, with annual revenue declining 16.7% year-over-year. A director's complete exit from equity ownership in an unprofitable, declining-revenue biotech company warrants investor attention to the company's cash runway and clinical pipeline prospects.

CFO Elena Ridloff sold 23,416 shares (32.7% reduction) across 3 days for $601,857.86 as SION hits 52-week high of $25.72.

Elena Ridloff, CFO and Head of Corporate Development at Sionna Therapeutics, executed 3 separate sales totaling 23,416 shares for $601,857.86 over consecutive days (August 26–28, 2025), reducing her holdings from 71,532 shares to 48,116 shares. The sales occurred at prices of $25.13, $25.10, and $25.97, with a blended average of $25.70—essentially at the current price of $25.72, which represents the 52-week high. The stock has appreciated 40.3% over the past 30 days and 87.9% over 90 days, creating a significant price window. As CFO, Ridloff's perspective on capital structure and financial health is material, and the sale of one-third of her holdings warrants investor attention, particularly given the company's net income of $-18.1M and market cap of $1.1B—indicating ongoing losses despite recent momentum.

SION CFO Elena Ridloff sells 52,000 shares (42.1% of holdings) in 2 transactions for $1.1M amid 86.6% 90-day rally

Elena Ridloff, CFO & Head of Corporate Development, executed 2 separate sales totaling 52,000 shares for $1,124,335.00 on consecutive days (Aug 19-20), reducing her holdings from 123,532 shares to 71,532 shares—a 42.1% reduction. The sales occurred at blended average price of $21.62, below the current price of $23.74, but notably within context of an 86.6% 90-day gain and stock trading near its 52-week high of $25.00. The company is unprofitable (net income of $-18,068,000.00) with a market cap of $1.0B. The substantial single-transaction reduction in CFO holdings during a period of significant equity appreciation warrants investor scrutiny of the underlying business fundamentals and whether this sale reflects capital deployment priorities or concerns about valuation at recent highs.